Metastasectomy for melanoma is associated with improved overall survival in responders to targeted molecular or immunotherapy. Issue 3 (22nd May 2020)

• Record Type: Journal Article
• Authors: Medina, Benjamin D.; Choi, Beatrix Hyemin; Rodogiannis, Kathy G.; Moran, Una; Shapiro, Richard L.; Pavlick, Anna; Osman, Iman; Berman, Russell S.; Lee, Ann Y.
• Is Part Of: Journal of surgical oncology. Volume 122:Issue 3(2020)
• Page Start: 555
• Page End: 561
• Publication Date: 2020-05-22
• Subjects: checkpoint blockade -- melanoma -- metastasectomy -- targeted molecular therapy; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.25987
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Background and Objectives: Metastasectomy for melanoma provides durable disease control in carefully selected patients. Similarly, BRAF‐targeted and immune checkpoint inhibition has improved median overall survival (OS) in metastatic patients. We hypothesized that there is an increasing role for metastasectomy in melanoma patients responding to these therapies. Methods: Retrospective analysis of a prospectively maintained database identified 128 patients with stage IV melanoma who received targeted molecular and/or checkpoint inhibitors at an academic institution from 2006 to 2017. Records were reviewed to characterize clinicopathologic characteristics, response to treatment, and intent of surgery for those who underwent metastasectomy. OS was analyzed by the Kaplan‐Meier method. Results: Median OS from stage IV diagnosis was 31.3 months. A total of 81 patients received checkpoint inhibitors, 11 received targeted inhibitors, and 36 received both. A total of 73 patients underwent metastasectomy. Indications for surgery included the intent to render disease‐free (54%), palliation (34%), and diagnostic confirmation (11%). Responders to systemic therapy who underwent metastasectomy had improved OS compared to responders who did not (84.3 vs. 42.9 months, P = .018). Conclusions: Metastasectomy for melanoma is associated with improved OS in patients that respond to targeted molecular or immunotherapy. Resection should be strongly considered in this cohort as multimodality treatment results in excellent OS.